Anebulo Pharmaceuticals (ANEB) Stock Statistics & Valuation Metrics

Anebulo Pharmaceuticals has a market cap or net worth of $15.50M. The enterprise value is $9.72M.

Anebulo Pharmaceuticals has 40,784,733 shares outstanding. The number of shares has decreased by -2.65% in one year.

Anebulo Pharmaceuticals’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -77.37%.

The current PE Ratio of Anebulo Pharmaceuticals is ―. Anebulo Pharmaceuticals’s PEG ratio is 0.26.

In the last 12 months, Anebulo Pharmaceuticals had revenue of 0.00 and earned -8.48M in profits. Earnings per share was -0.25.

In the last 12 months, operating cash flow was -5.84M and capital expenditures 0.00, giving a free cash flow of -5.84M billion.

Anebulo Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Anebulo Pharmaceuticals upcoming earnings date is Sep 23, 2026, After Close (Confirmed).

Anebulo Pharmaceuticals as a current ratio of 53.36, with Debt / Equity ratio of 0.00%

In the past 12 months, Anebulo Pharmaceuticals has paid 0.00 in taxes.

Anebulo Pharmaceuticals EV to EBITDA ratio is -4.80, with an EV/FCF ratio of -5.84.

Anebulo Pharmaceuticals has $9.04M in cash and marketable securities with $0.00 in debt, giving a net cash position of $9.04M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Anebulo Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―